Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: biowa who wrote (6747)	6/8/1999 9:40:00 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 9719

>> I think it's interesting that the clinical trials include q24h arms << Yeah, they even go so far as saying, in the 10-K, that 1X/day may be more effective than 2X/day. Doesn't register for me, but I won't complain. >> What have you heard about when we might hear from the PII BSI or PIII SSTI trials? << Nada, but haven't tried to hear. The Novartis agreement is in the new 10-Q. It's gutted, of course. Getting harder and harder to tell if a company has a valid path and agreement, or if they've done a "Robinson". Novartis is heads above every other company in picking off cheap technology during this slump, IMO. In ten years, there's going to be Novartis and a bunch of smaller companies (Merck et al.). Cheers! Rick